JP5298134B2 - 免疫抑制ポリペプチドおよび核酸 - Google Patents

免疫抑制ポリペプチドおよび核酸 Download PDF

Info

Publication number
JP5298134B2
JP5298134B2 JP2010532121A JP2010532121A JP5298134B2 JP 5298134 B2 JP5298134 B2 JP 5298134B2 JP 2010532121 A JP2010532121 A JP 2010532121A JP 2010532121 A JP2010532121 A JP 2010532121A JP 5298134 B2 JP5298134 B2 JP 5298134B2
Authority
JP
Japan
Prior art keywords
polypeptide
fusion protein
seq
amino acid
dimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010532121A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011502479A (ja
JP2011502479A5 (cg-RX-API-DMAC7.html
Inventor
エリック イー． カーラー
マダン エム． ペイドハンガット
スティーブン エイチ． バス
マーガレット ネイバーズ
ユハ プノネン
スティーブン ジェイ． チャピン
シュリダール ヴィシュワナータン
ブレント アール． ラーセン
Original Assignee
パーシード セラピューティクス リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パーシード セラピューティクス リミテッド ライアビリティ カンパニー filed Critical パーシード セラピューティクス リミテッド ライアビリティ カンパニー
Publication of JP2011502479A publication Critical patent/JP2011502479A/ja
Publication of JP2011502479A5 publication Critical patent/JP2011502479A5/ja
Application granted granted Critical
Publication of JP5298134B2 publication Critical patent/JP5298134B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2010532121A 2007-11-01 2008-10-15 免疫抑制ポリペプチドおよび核酸 Active JP5298134B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US98463107P 2007-11-01 2007-11-01
US60/984,631 2007-11-01
US5121508P 2008-05-07 2008-05-07
US61/051,215 2008-05-07
PCT/US2008/079981 WO2009058564A2 (en) 2007-11-01 2008-10-15 Immunosuppressive polypeptides and nucleic acids

Publications (3)

Publication Number Publication Date
JP2011502479A JP2011502479A (ja) 2011-01-27
JP2011502479A5 JP2011502479A5 (cg-RX-API-DMAC7.html) 2013-01-31
JP5298134B2 true JP5298134B2 (ja) 2013-09-25

Family

ID=40124836

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010532121A Active JP5298134B2 (ja) 2007-11-01 2008-10-15 免疫抑制ポリペプチドおよび核酸

Country Status (20)

Country Link
US (8) US7794718B2 (cg-RX-API-DMAC7.html)
EP (4) EP2222697B1 (cg-RX-API-DMAC7.html)
JP (1) JP5298134B2 (cg-RX-API-DMAC7.html)
KR (1) KR101383476B1 (cg-RX-API-DMAC7.html)
CN (2) CN103172750B (cg-RX-API-DMAC7.html)
AU (1) AU2008319053B2 (cg-RX-API-DMAC7.html)
CA (1) CA2703263C (cg-RX-API-DMAC7.html)
CY (1) CY1113713T1 (cg-RX-API-DMAC7.html)
DK (1) DK2222697T3 (cg-RX-API-DMAC7.html)
ES (2) ES2399088T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20130194T1 (cg-RX-API-DMAC7.html)
IL (1) IL205036A (cg-RX-API-DMAC7.html)
MX (1) MX2010004883A (cg-RX-API-DMAC7.html)
PH (1) PH12013501101A1 (cg-RX-API-DMAC7.html)
PL (2) PL2612868T3 (cg-RX-API-DMAC7.html)
PT (2) PT2612868T (cg-RX-API-DMAC7.html)
RU (1) RU2506275C2 (cg-RX-API-DMAC7.html)
TW (1) TWI448473B (cg-RX-API-DMAC7.html)
WO (1) WO2009058564A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201002872B (cg-RX-API-DMAC7.html)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
CA2587617C (en) 2004-11-12 2011-02-01 Xencor, Inc. Fc variants with altered binding to fcrn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
KR101580937B1 (ko) 2007-06-01 2015-12-31 유니버시티 오브 매릴랜드, 발티모어 면역글로불린 불변영역 Ｆｃ 수용체 결합제
EP2222697B1 (en) 2007-11-01 2012-12-05 Perseid Therapeutics LLC Immunosuppressive polypeptides and nucleic acids
MX2010005317A (es) * 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
KR20180105731A (ko) 2008-10-02 2018-09-28 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Ｃｄ86 길항제 다중-표적 결합 단백질
JP5926680B2 (ja) * 2009-07-28 2016-05-25 リガセプト・エルエルシー 広範囲のＥｒｂＢリガンド結合分子ならびにそれを調製および使用するための方法
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US10813917B2 (en) * 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
KR101193940B1 (ko) * 2009-12-14 2012-10-24 고려대학교 산학협력단 레서스 원숭이 ｃｔｌａ-4 융합 이뮤노글로불린
PT3053932T (pt) * 2010-02-19 2020-10-21 Xencor Inc Novas imunoadesinas ctla4-ig
KR20130049775A (ko) * 2010-03-12 2013-05-14 애브비 바이오테라퓨틱스 인크. Ｃｔｌａ４ 단백질 및 이의 용도
US9169325B2 (en) 2010-04-13 2015-10-27 Celldex Therapeutics, Inc. Antibodies that bind human CD27 and uses thereof
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
DK2598533T3 (en) 2010-07-28 2019-04-23 Gliknik Inc Fusion proteins of natural human protein fragments to create in an orderly fashion multimerized immunoglobulin FC compositions
EP2670434B1 (en) * 2011-01-31 2018-12-26 Tau Bio-Logic Corp. Treatment of tauopathies
WO2012116280A2 (en) * 2011-02-24 2012-08-30 Paxvax, Inc. Formulations useful for spray drying vaccines
WO2012159075A1 (en) * 2011-05-19 2012-11-22 Seattle Biomedical Research Institute Bioprobe compositions and their methods of use
CN102382193B (zh) * 2011-11-01 2013-08-14 孙嘉琳 诱导和激活癌靶向t细胞的融合蛋白及制备方法及用途
CN102391377B (zh) * 2011-11-01 2013-11-06 孙嘉琳 一种可诱导和激活癌靶向t细胞的融合蛋白及制备方法及用途
CN102516392B (zh) * 2011-11-25 2014-05-28 孙嘉琳 一种癌靶向超抗原融合蛋白及制备方法及用途
JP2015506372A (ja) * 2012-01-27 2015-03-02 グリックニック インコーポレイテッド ＩｇＧ２ヒンジドメインを含む融合タンパク質
RU2671465C2 (ru) 2012-05-11 2018-10-31 Медиммьюн Лимитед Варианты ctla-4
US20160194660A1 (en) * 2012-12-21 2016-07-07 Merck Sharp & Dohme Corp. Expression vectors for recombinant protein production in mammalian cells
EP2855533A4 (en) 2013-03-15 2015-11-25 Momenta Pharmaceuticals Inc METHODS RELATING TO CTLA4-FC FUSION PROTEINS
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
CN104277112B (zh) 2013-07-04 2018-01-26 嘉和生物药业有限公司 长效降血糖融合蛋白
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US11340235B2 (en) 2014-02-28 2022-05-24 Ga Generic Assays Gmbh GP2 isoforms and their use in autoantibody capture
CN103923934B (zh) * 2014-03-22 2016-11-02 复旦大学 一种具有免疫负调控作用的基因工程蛋白及其制备方法与应用
AU2015249376C1 (en) 2014-04-25 2019-10-31 2Seventy Bio, Inc. Improved methods for manufacturing adoptive cell therapies
CA2956002C (en) 2014-07-24 2023-06-27 Bluebird Bio, Inc. Bcma chimeric antigen receptors
EP2982693A1 (en) * 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
AU2015360845B2 (en) 2014-12-12 2020-11-26 2Seventy Bio, Inc. BCMA chimeric antigen receptors
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
WO2016174082A1 (en) * 2015-04-28 2016-11-03 Swedish Orphan Biovitrum Ab (Publ) Compositions comprising anakinra
CN108368165A (zh) * 2015-06-24 2018-08-03 德克萨斯大学系统董事会 用于治疗颅内出血相关症状的方法和组合物
FI3325011T6 (fi) 2015-07-24 2023-05-11 Ihmisen proteiinifragmenttien fuusioproteiineja järjestyksenmukaisesti multimerisoitujen, paremmin komplementtia sitovien immunoglobuliini-fc-koostumusten muodostamiseksi
CN108137659B (zh) 2015-08-21 2021-11-26 汉阳大学校产学协力团 具有预防或治疗中枢神经系统疾病作用的肽和包含其作为活性成分的药物组合物
WO2017034244A1 (ko) * 2015-08-21 2017-03-02 한양대학교 산학협력단 중추신경계 질환에 대한 예방 또는 치료효과를 갖는 펩타이드 및 이를 유효성분으로 하는 중추신경계 질환 예방 및 치료용 약학적 조성물
US11351224B2 (en) 2015-08-21 2022-06-07 Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) Pharmaceutical composition for preventing and treating transplant rejection
JP2018527350A (ja) * 2015-09-01 2018-09-20 イミュンワーク インク．Ｉｍｍｕｎｗｏｒｋ Ｉｎｃ． 血餅形成の予防及び／又は血栓症の治療のための分子構築物
MX2018005517A (es) * 2015-11-02 2018-11-09 Five Prime Therapeutics Inc Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer.
KR20190006495A (ko) 2016-04-15 2019-01-18 알파인 이뮨 사이언시즈, 인코포레이티드 Cd80 변이체 면역조절 단백질 및 그의 용도
AU2017279538A1 (en) 2016-06-07 2019-01-03 Gliknik Inc. Cysteine-optimized stradomers
WO2017214834A1 (zh) * 2016-06-14 2017-12-21 石庆学 特异促进 ctla-4 基因高表达的慢病毒表达载体及其应用
CN107815468B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
WO2018041121A1 (en) * 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric ctla-4
JP7093346B2 (ja) 2016-11-04 2022-06-29 ２セブンティ バイオ インコーポレイテッド 抗ｂｃｍａ ｃａｒ ｔ細胞組成物
IL266988B2 (en) 2016-12-09 2024-11-01 Gliknik Inc Methods of treating inflammatory disorders with multivalent fc compounds
WO2018107079A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Manufacturing optimization of gl-2045, a multimerizing stradomer
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
EP3628070B1 (en) * 2017-04-28 2021-09-08 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides for use in increasing central memory t cells
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
SG11202003078VA (en) 2017-10-18 2020-05-28 Alpine Immune Sciences Inc Variant icos ligand immunomodulatory proteins and related compositions and methods
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
KR20210011919A (ko) 2018-04-17 2021-02-02 셀덱스 쎄라퓨틱스, 인크. 항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물
US20210347849A1 (en) * 2018-07-24 2021-11-11 Good T Cells, Inc. Composition for Preventing or Treating Immune-Related Diseases
CN112543642A (zh) * 2018-08-29 2021-03-23 戊瑞治疗有限公司 CD80胞外结构域Fc融合蛋白给药方案
WO2020088645A1 (en) * 2018-11-02 2020-05-07 Beijing Vdjbio Co., Ltd. Modified ctla4 and methods of use thereof
EP3948281A1 (en) 2019-03-29 2022-02-09 F. Hoffmann-La Roche AG Spr-based binding assay for the functional analysis of multivalent molecules
CN113874078B (zh) 2019-04-05 2025-05-06 Tauc3生物制品有限公司 抗tauc3抗体及其应用
WO2020210596A1 (en) * 2019-04-10 2020-10-15 University Of Kentucky Research Foundation Modified prostate apoptosis response-4 (par-4) polypeptide, and methods of production and use
JP7405361B2 (ja) * 2019-10-21 2023-12-26 東亞合成株式会社 抗腫瘍ペプチドおよびその利用
RU2760578C2 (ru) * 2019-12-25 2021-11-29 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Слитый белок, содержащий модифицированный безметиониновый белок GroEL и димер полипептида полифемузина I
CN111592580A (zh) * 2020-05-08 2020-08-28 中国药科大学 一种具有免疫检查点ctla-4抑制活性的多肽及其应用
EP3957649A1 (en) 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
CU24723B1 (es) * 2021-01-29 2024-12-09 Ct Ingenieria Genetica Biotecnologia Composición farmacéutica que comprende el ghrp-6
US20240122990A1 (en) * 2021-02-23 2024-04-18 University Of Washington Compositions and methods for cardiomyocyte transplantation
US11993657B2 (en) * 2021-03-16 2024-05-28 Jn Biosciences Llc Bifunctional molecules for treatment of immune disorders
EP4323388B1 (en) 2021-04-16 2025-01-29 Athebio AG N-terminal capping modules of ankyrin repeat domains
WO2023021050A1 (en) 2021-08-17 2023-02-23 Athebio Ag Variants of ankyrin repeat domains
EP4137508A1 (en) 2021-08-17 2023-02-22 Athebio AG Variants of ankyrin repeat domains
CN115719614A (zh) * 2021-08-27 2023-02-28 予果生物科技（北京）有限公司 一种基于隐藏亚组的生信降噪分析方法及系统
CN118401548A (zh) * 2021-11-26 2024-07-26 伊蒙纽斯治疗有限公司 细胞表面上的结合结构域分子
CA3242952A1 (en) * 2021-12-17 2025-04-29 Kashiv Biosciences, Llc IMPROVED DOSAGE METHOD FOR DETERMINING THE POTENCY OF A RECOMBINATING PROTEIN
WO2023244760A1 (en) * 2022-06-15 2023-12-21 Duke University Protein library display systems and methods thereof
WO2024037743A1 (en) 2022-08-16 2024-02-22 Athebio Ag Variants of ankyrin repeat domains
EP4573106A2 (en) 2022-08-16 2025-06-25 Athebio AG Variants of ankyrin repeat domains

Family Cites Families (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US511A (en) * 1837-12-15 Improved mode of coloring and finishing leather
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
BR7908410A (pt) 1978-12-22 1980-09-09 Biogen Nv Meio para deteccao de anticorpos de vhb no soro do sangue,e processo para deteccao da presenca da infeccao por virus da hepatite b em seres humanos
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
CA1200773A (en) 1980-02-29 1986-02-18 William J. Rutter Expression linkers
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
JPS60188070A (ja) 1984-03-09 1985-09-25 Kunio Yamane シグナルペプチドをコードするｄｎａ
GB8412517D0 (en) 1984-05-16 1984-06-20 Nagai K Recombinant fusion proteins
CA1282721C (en) 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
CA1341423C (en) 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
ATE68013T1 (de) 1985-07-05 1991-10-15 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
KR890003620Y1 (ko) 1985-07-25 1989-05-27 삼성전자주식회사 전자레인지의 파워릴레이 구동회로
CA1293460C (en) 1985-10-07 1991-12-24 Brian Lee Sauer Site-specific recombination of dna in yeast
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5084384A (en) 1987-04-23 1992-01-28 Monsanto Company Secretion of insulin-like growth factor-I
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
US5017478A (en) 1987-07-16 1991-05-21 Berlex Laboratories, Inc. Transfected cells containing plasmids having genes oriented in opposing directions and methods of using
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
ZA887365B (en) 1987-10-02 1990-05-30 Genentech Inc Adheson variants
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US6710169B2 (en) * 1987-10-02 2004-03-23 Genentech, Inc. Adheson variants
DE68926888T2 (de) 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5614404A (en) 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5284768A (en) 1988-08-24 1994-02-08 Sanofi Signal peptide, DNA sequences coding for the latter, expression vectors carrying one of these sequences, gram-negative bacteria transformed by these vectors, and process for the periplasmic production of a polypeptide
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US6685941B1 (en) * 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
DE3901681A1 (de) 1989-01-21 1990-07-26 Behringwerke Ag Signalpeptid fuer die sekretion von peptiden in escherichia coli, verfahren zu seiner gewinnung und seine verwendung
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6406697B1 (en) * 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
EP0497922B1 (en) 1989-10-24 2002-01-30 Chiron Corporation Infective protein delivery system
JP3056782B2 (ja) 1989-11-03 2000-06-26 ヴァンダービルト ユニバーシティ 標的器官内での遺伝子の発現用医薬組成物
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US5672510A (en) 1990-01-19 1997-09-30 Genetic Therapy, Inc. Retroviral vectors
US7070776B1 (en) * 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
HUT67762A (en) 1991-03-19 1995-04-28 Cytrx Corp Polyoxypropylene/polyoxiethylene copolymers with improved biological activity and process for producing thereof
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US6887471B1 (en) * 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
AU661854B2 (en) * 1991-06-27 1995-08-10 Bristol-Myers Squibb Company CTL4A receptor, fusion proteins containing it and uses thereof
US5506098A (en) 1991-09-04 1996-04-09 Daikin Industries, Ltd. In situ hybridization method
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
DE69333580D1 (de) 1992-04-07 2004-09-09 Univ Michigan Immunregulation über die cd28-route
US5792751A (en) 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
EP0671926B1 (en) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US5773253A (en) * 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
EP0621337A1 (en) 1993-01-25 1994-10-26 American Cyanamid Company Codon optimized DNA sequence for insect toxin AaIT
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US6482919B2 (en) * 1993-02-01 2002-11-19 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
ATE386800T1 (de) 1993-03-17 2008-03-15 Us Gov Health & Human Serv Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
TW404844B (en) 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
PT702723E (pt) 1993-04-21 2003-01-31 Pasteur Institut Implante biocompativel para a expressao e a secrecao in vivo de um composto terapeutico
US5591601A (en) 1993-05-14 1997-01-07 Ohio University Edison Animal Biotechnology Institute DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
DE69433461T2 (de) 1993-09-15 2004-11-18 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Rekombinanter Alphavirus Vektor
US6107095A (en) 1993-11-26 2000-08-22 Mazurkiewicz; Marian Method for introducing substances into living cells and tissues
US5580766A (en) 1994-01-14 1996-12-03 Alexion Pharmaceuticals, Inc. Retroviral vector particles for transducing non-proliferating cells
DE69529495T2 (de) 1994-01-21 2003-06-12 Powderject Vaccines, Inc. Gasbetätigtes element zum austragen von genmaterial
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
GB9406974D0 (en) 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
US5601820A (en) 1994-07-07 1997-02-11 Children's Hospital Of Philadelphia Compositions and methods of making and using human full length TRK-B
US5855579A (en) * 1994-07-15 1999-01-05 Smith & Nephew, Inc. Cannulated modular intramedullary nail
EP1181937A3 (en) 1994-08-09 2004-02-04 Cytrx Corporation Novel vaccine adjuvant and vaccine
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
US6127525A (en) 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5750340A (en) 1995-04-07 1998-05-12 University Of New Mexico In situ hybridization solution and process
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US5525510A (en) 1995-06-02 1996-06-11 Agracetus, Inc. Coanda effect gene delivery instrument
WO1996039514A1 (en) 1995-06-05 1996-12-12 The University Of Washington Method for prolonging the expression of a gene of interest using soluble ctla4 molecules
US5993800A (en) * 1995-06-05 1999-11-30 Bristol-Myers Squibb Company Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand
US5668110A (en) 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5811406A (en) 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
AU6691496A (en) 1995-08-01 1997-02-26 Advanced Therapies, Inc. Enhanced artificial viral envelopes for cellular delivery of therapeutic substances
US5966560A (en) * 1995-08-29 1999-10-12 Minolta Co., Ltd. Image forming apparatus with enhanced pretransfer erasing
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US7041634B2 (en) * 1995-09-27 2006-05-09 Emory University Method of inhibiting immune system destruction of transplanted viable cells
WO1997011607A1 (en) 1995-09-27 1997-04-03 Emory University Method of inhibiting immune system destruction of transplanted viable cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
EP0914344B8 (en) * 1996-03-04 2005-08-10 Scios Inc. ASSAY AND REAGENTS FOR QUANTIFYING hBNP
DK0892643T4 (da) * 1996-03-20 2009-12-14 Bristol Myers Squibb Co Fremgangsmåder til inhibering af et immunrespons ved blokering af GP39/CD40- og CTLA4/CD28/B7-banerne og præparater til anvendelse derved
US6261552B1 (en) 1997-05-22 2001-07-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus vectors
WO1997044446A1 (en) 1996-05-24 1997-11-27 University Of Maryland At Baltimore Dna vaccines for eliciting a mucosal immune response
US5750356A (en) 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
GB9619002D0 (en) 1996-09-11 1996-10-23 Oxford Biosciences Ltd Particle delivery
AU3359497A (en) 1996-07-11 1998-02-09 Takara Shuzo Co., Ltd. Method for effecting site-directed mutagenesis
EP0920522B1 (en) 1996-08-14 2003-10-29 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES A vector for polynucleotide vaccines
US6211160B1 (en) 1996-09-06 2001-04-03 The Trustees Of The University Of Pennsylvania Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6107477A (en) 1996-09-26 2000-08-22 Aurora Biosciences Corporation Non-optimal Kozaks sequences
WO1998017323A1 (en) 1996-10-23 1998-04-30 The Trustees Of The University Of Pennsylvania Improved vaccines
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
KR100503701B1 (ko) 1996-11-20 2005-07-26 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법
NZ336838A (en) 1997-01-29 2002-04-26 Cornell Res Foundation Inc A method of enhancing the level of perfusion of blood to a target tissue by administering an adenoviral vector encoded with an angiogenic peptide within 0.5-15 cm3 of the tissue
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US6110161A (en) 1997-04-03 2000-08-29 Electrofect As Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US6225082B1 (en) 1997-05-09 2001-05-01 Research Corporation Technologies, Inc. Myelin basic protein MRNA transport and translation enhancer sequences
CA2293489C (en) 1997-06-06 2009-09-29 The Regents Of The University Of California Inhibitors of dna immunostimulatory sequence activity
EP0996735B1 (en) 1997-06-09 2003-12-10 Genvec, Inc. Chimeric vectors comprising a phage packaging site and a portion derived from the genome of a eukaryotic virus
DE19729058A1 (de) 1997-07-08 1999-01-14 Sika Ag Verbundelement und Verfahren zu seiner Herstellung
US6165476A (en) 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
WO1999004009A1 (en) 1997-07-14 1999-01-28 Wisconsin Alumni Research Foundation Method of dna vaccination using dna encoding antigen and encoding il6
WO1999008689A1 (en) 1997-08-21 1999-02-25 Powderject Vaccines, Inc. Mucosal immunization using particle-mediated delivery techniques
CA2304173A1 (en) 1997-09-23 1999-04-01 Genvec, Inc. Plasmids for construction of eukaryotic viral vectors
US5932445A (en) 1997-11-07 1999-08-03 Incyte Pharmaceuticals, Inc. Signal peptide-containing proteins
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999041402A2 (en) 1998-02-11 1999-08-19 Maxygen, Inc. Targeting of genetic vaccine vectors
US6087341A (en) 1998-02-12 2000-07-11 The Board Of Trustees Of The Leland Standford Junior University Introduction of nucleic acid into skin cells by topical application
US5922576A (en) 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
AU3107699A (en) 1998-03-19 1999-10-11 Heska Corporation Novel forms of t cell costimulatory proteins, nucleic acid molecules, and uses thereof
US6121236A (en) 1998-03-24 2000-09-19 The Children's Medical Center Corporation Multivalent ligands which modulate angiogenesis
EA200001096A1 (ru) 1998-04-22 2001-04-23 Джинвек, Инк. Способ обогащения раствора аденовируса, способ точного подсчета числа аденовирусных частиц в образце раствора (варианты) и способ очистки аденовируса из клеток, инфицированных аденовирусом
WO1999057275A1 (en) 1998-05-06 1999-11-11 Pharmacia & Upjohn Company Introduction of naked dna or rna encoding non-human vertebrate peptide hormones or cytokines into a non-human vertebrate
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US5965358A (en) 1998-08-26 1999-10-12 Genvec, Inc. Method for assessing the relative purity of viral gene transfer vector stocks
WO2000015823A1 (en) 1998-09-11 2000-03-23 Genvec, Inc. Alternatively targeted adenovirus
US6800457B2 (en) * 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6521419B1 (en) * 1998-09-22 2003-02-18 Kanakaraju Koduri Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6225113B1 (en) 1998-12-04 2001-05-01 Genvec, Inc. Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
ATE465266T1 (de) 1998-12-31 2010-05-15 Novartis Vaccines & Diagnostic Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren
IL144084A0 (en) 1999-02-03 2002-05-23 Biosante Pharmaceuticals Inc Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
WO2001081609A2 (en) 2000-03-22 2001-11-01 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US6168941B1 (en) 2000-04-07 2001-01-02 Genvec, Inc. Method of producing adenoviral vector stocks
WO2001081553A1 (en) 2000-04-25 2001-11-01 Chiron Corporation Alphavirus-based vectors for persistent infection
US20020058039A1 (en) 2000-04-27 2002-05-16 Coyne Michael J. Method of measuring the duration of adequate immune memory in companion animals
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
MXPA02011534A (es) 2000-05-26 2004-08-12 Bristol Myers Squibb Co Moleculas mutantes ctla4 solubles y uso de las mismas.
US7074590B2 (en) 2000-06-23 2006-07-11 Maxygen, Inc. Chimeric promoters
EP1360290A2 (en) * 2000-06-23 2003-11-12 Maxygen, Inc. Co-stimulatory molecules
US20050154189A1 (en) * 2000-06-23 2005-07-14 Maxygen Inc Novel co-stimulatory molecules
US7183376B2 (en) * 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
CZ303959B6 (cs) * 2000-07-03 2013-07-17 Bristol-Myers Squibb Company Solubilní CTLA4 fúzní molekula, farmaceutický prostredek s jejím obsahem a její pouzití
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7067626B2 (en) * 2000-07-05 2006-06-27 Pharmacia & Upjohn Company Human ion channel proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
PT1397153E (pt) * 2001-05-23 2008-06-12 Bristol Myers Squibb Co Métodos para proteger um transplante alogénico de ilhéus utilizando moléculas mutantes de ctla4 solúveis
FR2843396B1 (fr) * 2002-08-07 2005-04-15 Bio Rad Pasteur Anticorps specifiques pour le diagnostic de l'insuffisance cardiaque
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
PL377603A1 (pl) * 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Poprawa jakości produktu w hodowlach komórek ssaczych do wytwarzania białka
EP1670499A4 (en) * 2003-08-04 2009-07-22 Bristol Myers Squibb Co METHODS OF TREATING A CARDIOVASCULAR DISEASE USING A SOLUBLE CTLA4 MOLECULE
US7731965B2 (en) * 2005-02-17 2010-06-08 Abbott Lab Human ring specific BNP antibodies
DK2586459T3 (en) 2005-03-25 2017-09-11 Regeneron Pharma VEGF antagonist formulations
PL1868635T3 (pl) 2005-04-06 2017-10-31 Bristol Myers Squibb Co Metody leczenia zaburzeń immunologicznych związanych z transplantacją narządów rozpuszczalnymi zmutowanymi cząsteczkami CTLA4
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
EP2222697B1 (en) * 2007-11-01 2012-12-05 Perseid Therapeutics LLC Immunosuppressive polypeptides and nucleic acids
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit

Also Published As

Publication number Publication date
US20090258031A1 (en) 2009-10-15
CN101998965A (zh) 2011-03-30
US7794718B2 (en) 2010-09-14
EP2612868B1 (en) 2018-08-15
DK2222697T3 (da) 2013-03-11
US20110166324A1 (en) 2011-07-07
CN101998965B (zh) 2014-03-12
AU2008319053B2 (en) 2012-04-26
EP2385065A1 (en) 2011-11-09
US8491899B2 (en) 2013-07-23
CY1113713T1 (el) 2016-06-22
ES2399088T3 (es) 2013-03-25
RU2506275C2 (ru) 2014-02-10
WO2009058564A3 (en) 2010-01-14
HRP20130194T1 (hr) 2013-04-30
CN103172750A (zh) 2013-06-26
PH12013501101B1 (en) 2015-12-07
WO2009058564A2 (en) 2009-05-07
KR20100105551A (ko) 2010-09-29
PH12013501101A1 (en) 2015-12-07
CA2703263C (en) 2014-03-18
US8496935B2 (en) 2013-07-30
MX2010004883A (es) 2010-11-10
US20110130546A1 (en) 2011-06-02
US8318176B2 (en) 2012-11-27
IL205036A (en) 2016-02-29
TW200936607A (en) 2009-09-01
PL2612868T3 (pl) 2018-12-31
US20110177071A1 (en) 2011-07-21
IL205036A0 (en) 2010-11-30
ZA201002872B (en) 2011-02-23
US20110159542A1 (en) 2011-06-30
KR101383476B1 (ko) 2014-04-11
US8283447B2 (en) 2012-10-09
JP2011502479A (ja) 2011-01-27
TWI448473B (zh) 2014-08-11
US20100260759A1 (en) 2010-10-14
CN103172750B (zh) 2014-12-10
EP2612868A1 (en) 2013-07-10
CA2703263A1 (en) 2009-05-07
RU2010122053A (ru) 2011-12-10
AU2008319053A1 (en) 2009-05-07
US8268587B2 (en) 2012-09-18
PL2222697T3 (pl) 2013-05-31
US20110182898A1 (en) 2011-07-28
EP2222697B1 (en) 2012-12-05
EP2222697A2 (en) 2010-09-01
ES2688721T3 (es) 2018-11-06
EP2612867A1 (en) 2013-07-10
US20110129875A1 (en) 2011-06-02
US8445230B2 (en) 2013-05-21
PT2222697E (pt) 2013-02-15
PT2612868T (pt) 2018-10-24
US8071095B2 (en) 2011-12-06

Similar Documents

Publication Publication Date Title
JP5298134B2 (ja) 免疫抑制ポリペプチドおよび核酸
KR20180012260A (ko) 조율가능한 친화성을 갖는 면역조절 단백질
AU2014250683B2 (en) Immunosuppressive polypeptides and nucleic acids
CA2805976C (en) Immunosuppressive polypeptides and nucleic acids
AU2012202324B2 (en) Immunosuppressive polypeptides and nucleic acids

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121204

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20121219

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20130110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130322

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130617

R150 Certificate of patent or registration of utility model

Ref document number: 5298134

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250